Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Aspect Biosystems and Novo Nordisk Collab on Bioprinted Tissue Treatment

Aspect Biosystems and Novo Nordisk Collab on Bioprinted Tissue Treatment

21st April 2023

Aspect Biosystems and Novo Nordisk have launched a collaboration to create bioprinted tissue treatments that may either substitute, enhance, or repair biological processes in the human body.

The objective of this is introducing a new generation of diabetic and obesity medications that significantly delays the progression of the condition.

According to the terms of the contract, Novo Nordisk will be granted an exclusive, global license to take advantage of Aspect’s bioprinting technology. With this, they can create a maximum of four diabetes and/or obesity therapy solutions.

Aspect will be paid an initial rate totaling $75 million, which includes an upfront payment. Aspect will be entitled to receive subsequent milestone rewards totaling up to 650 million dollars per product, in addition to tiered royalties on other potential product sales.

Aspect will be given $75 million to jumpstart the process, within which is an upfront fee. Following this,

Aspect Biosystem’s CEO, Tamer Mohamed, expressed that “this partnership leverages Aspect’s full-stack tissue therapeutic platform, talented team and bold vision, and reinforces our strategy to create bioprinted tissue therapeutics with global industry leaders while advancing our internal therapeutic pipeline.”

Jacob Sten Petersen explained: “Novo Nordisk has built strong capabilities when it comes to producing functional and highly pure therapeutic replacement cells at the highest quality and at scale. Collaborating with Aspect Biosystems adds an important component to our strategy to develop comprehensive cell therapy products.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.